Multiomics-based efforts to identify therapeutic targets for IBD have been limited to
European populations. Prior reports on heterogeneity between East Asians and Europeans …

Background Genome-wide association studies (GWASs) have identified 320 loci associated
with inflammatory bowel disease (IBD). About 15% of these loci include genes that lie in …

Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …

Inflammatory bowel diseases (IBD) are characterized by idiopathic chronic inflammation of
the gastrointestinal tract, comprising the two major entities ulcerative colitis (UC) and …

Background Genome-wide association studies (GWASs) have identified 243 loci associated
with inflammatory bowel disease (IBD). However, the mapping of additional disease loci and …

Background Inflammatory bowel disease (IBD) is a complex disease characterised by
chronic inflammation of the digestive tract. Genome-wide association studies (GWAS) have …

Patients with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's
disease, are at higher risk to develop colorectal cancer (CRC). However, the underlying …

Background Limited investigations were performed to explore the relationships of
inflammatory bowel disease (IBD), Crohn's disease (CD), and Ulcerative colitis (UC) with …

Background Mendelian randomization (MR) was used to evaluate the bidirectional causal
relationship between inflammatory bowel disease (IBD) and interleukins (ILs), chemokines …

Inflammatory bowel disease (IBD) is an immune-mediated chronic intestinal disorder with
major phenotypes: ulcerative colitis (UC) and Crohn's disease (CD). Multiple studies have …